Litcius/Paper detail

Inhaled Levodopa (CVT-301) for the Treatment of Parkinson Disease

Glenardi Glenardi, Tutwuri Handayani, Jimmy Barus, Ghea Mangkuliguna

2021Neurology Clinical Practice13 citationsDOIOpen Access PDF

Abstract

Purpose of Review: To investigate the efficacy and safety of CVT-301 in treating motor fluctuation in patients with Parkinson disease (PD). Recent Findings: = 0.05). Summary: CVT-301 had the potential to be an alternative or even a preferred treatment for motor fluctuation in patients with PD.

Topics & Concepts

LevodopaParkinson's diseaseNauseaOdds ratioRating scaleInternal medicineConfidence intervalMedicinePlaceboAdverse effectPhysical therapyAnesthesiaDiseasePsychologyPathologyDevelopmental psychologyAlternative medicineAmyotrophic Lateral Sclerosis ResearchCystic Fibrosis Research AdvancesParkinson's Disease Mechanisms and Treatments
Inhaled Levodopa (CVT-301) for the Treatment of Parkinson Disease | Litcius